Chemokine's lead anticancer drug to be studied by M.D. Anderson center

New York, Feb. 21 - Chemokine Therapeutics Corp. said that the University of Texas M.D. Anderson Cancer Center of Houston will study its lead anticancer compound, CTCE-9908, for breast cancer.

Under the agreement, oncologists at the hospital will investigate CTCE-9908's ability to inhibit the metastasis of a human breast cancer in preclinical models.

In previous experimental studies, CTCE-9908 has been shown to reduce cancer metastases by 50% to 70%, the company said.

CTCE-9908 is a chemokine CXCR4 antagonist. The CXCR4 receptor is present on most human tumors cells, including lung, breast, prostate, colon, ovarian, bone, brain and skin cancer, and has been observed to contribute to invasion of cancer to distant sites from the primary tumor, a process known as metastasis. Leading cancer researchers have demonstrated that a high level of CXCR4 expression in cancer cells is correlated to tumor progression, high metastasis rate and low patient survival rate.

A phase 1 trial in healthy volunteers has already shown CTCE-9908 to be safe and well tolerated. Chemokine expects to launch during the first quarter a phase 1b/2 clinical trial to demonstrate safety and explore early signs of efficacy after repeat administration of CTCE-9908 in a late-stage cancer setting.

Chemokine is a Vancouver, B.C., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.